Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Allergo Journal
Erschienen in: Allergo Journal 2/2020

25.03.2020 | Prämedikation | Übersicht

Natural history of systemic reactions and risk factors in children and adults with Hymenoptera venom allergy

verfasst von: Darío Antolín-Amérigo, Berta Ruiz-León, A. Vega-Castro, Belén de la Hoz Caballer

Erschienen in: Allergo Journal | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose: Stings by Hymenoptera usually cause just local reactions. However, in some cases, they can induce systemic symptoms and even fatal reactions. The natural history and the risk factors of severe systemic reactions are presented in this review.
Methods: Both the natural history and risk factors of systemic reactions due to insect stings are unraveled. This publication is based on a selective literature search in PubMed, Web of Science, and EMBASE (until 30 July 2019). Recent publications about insect venom allergy in English journals were analyzed. This literature search included original and review articles and relevant abstracts of allergy congresses in English.
Results: Risk factors are classified as follows: (1) patient-related, (2) allergen-related and (3) reaction-related and also risk factor associated to venom immunotherapy (VIT) are considered. Due to the scarcity of data about the suitability of premedication before and during VIT, a succinct table gathering available premedication invites further investigation.
Conclusions: There is limited evidence with regard to the natural history of HVA both in adults and in children. Several risk factors may influence the natural history of HVA, namely patient-related, allergen-related and reaction-related. Other factors are inherent to the use of venom immunotherapy (VIT).
Literatur
1.
Sturm GJ, Varga EM, Roberts G, Mosbech H, Bilò MB, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: hymenopteravenomallergy. Allergy 2018;73:744-64PubMedCrossRef
2.
Pesek RD, Lockey RF. Treatment of hymenoptera venom allergy: an update. Curr Opin Allergy Clin Immunol 2014;14:340-8PubMedCrossRef
3.
Ollert M, Blank S. Anaphylaxis to insect venom allergens: role of molecular diagnosis. Curr Allergy Asthma Rep 2015;15:2
4.
Elberink JN, Dubois AE. Quality of life in insect venom allergic patients. Curr Opin Allergy Clin Immunol 2003;3:287-93
5.
Alfaya T, Vega A, Domínguez-Noche C, Ruíz B, Marques L, Sánchez-Morillas L. Longitudinal validation of the Spanish versionofthehealth-relatedquality of lifequestionnaire for hymenoptera venom allergy (HRQLHA). J Investig Allergol ClinImmunol 2015;25:426-30
6.
Armisén M, Guspi R, Alfaya T, Crus S, Fernández S, Domínguez-Noche C, et al. Cross-sectional validation of a quality of life questionnaire in Spanish for patients allergic to hymenoptera venom. J Investig Allergol Clin Immunol 2015;25:176-82
7.
Antolín-Amérigo D, Ruiz-León B, Boni E, Alfaya-Arias T, Álvarez-Mon M, Barbarroja-Escudero J, et al. Component-resolved diagnosis in hymenoptera allergy. Allergol Immunopathol 2018;46:253-62PubMedCrossRef
8.
Alfaya Arias T, Soriano Gómis V, Soto MeraT, Vega Castro A, Vega Gutiérrez JM, Alonso Llamazares A, et al. Key issues in hymenoptera venom allergy: an update. J Investig Allergol Clin Immunol 2017;27:19-31PubMedCrossRef
9.
Lange J, Cichocka-Jarosz E, Marczak H, Krauze A, Tarczon I, ´Swiebocka E, et al. Natural history of hymenoptera venom allergy in children not treated with immunotherapy. Ann Allergy Asthma Immunol 2016;116:225-9CrossRef
10.
Worm M, Francuzik W, Renaudin JM, Bilò MB, Cardona V, Scherer Hofmeier K, et al. Factors increasing the risk for a severe reaction in anaphylaxis: ananalysis of data from the European anaphylaxis registry. Allergy 2018;73:1322-30PubMedCrossRef
11.
Chen W, Mempel M, Schober W, Behrendt H, Ring J. Gender, difference, sex hormones, and immediate type hypersensitivity reactions. Allergy 2008;63:1418-27PubMedCrossRef
12.
Ruëff F, Przybilla B, Bilò MB, Müller U, Scheipl F, Aberer W, et al. Predictors of severe systemic anaphylactic reactions in patients with hymenoptera venom allergy: importance of baseline serumtryptase — a study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. J Allergy Clin Immunol 2009;124:1047-54CrossRef
13.
Bonadonna P, Scaffidi L. Hymenoptera anaphylaxis as a clonal mast cell disorder. Immunol Allergy Clin North Am 2018;38:455-68PubMedCrossRef
14.
Alvarez-Twose I, Matito A. Mastocytosis presenting as insect anaphylaxis: gender differences and natural history. Curr Opin Allergy Clin Immunol 2019;19:1468-74PubMedCrossRef
15.
González de Olano D, de la Hoz Caballer B, Núñez López R, Sánchez Muñoz L, Cuevas Agustín M, Diéguez MC, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). ClinExpAllergy 2007;37:1547-55
16.
Bonadonna P, Zanotti R, Müller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010;10:347-53PubMedCrossRef
17.
Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, et al. Clonal mast cell disorders in patients with systemic reactions to hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009;123:680-6CrossRef
18.
Vazquez-Revuelta P, Gonzalez-de-Olano D. Prevalence of clonal mast cell disorders in patients presenting with hymenoptera venom anaphylaxis might be higher than expected. J Investig Allergol Clin Immunol 2018;28:193-4PubMedCrossRef
19.
Alvarez-Twose I, Zanotti R, González-de-Olano D, Bonadonna P, Vega A, Matito A, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol 2014;133:520-8CrossRef
20.
Zanotti R, Lombardo C, Passalacqua G, Caimmi C, Bonifacio M, De Matteis G, et al. Clonal mast cell disorders in patients with severe hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol 2015;136:135-9CrossRef
21.
Vos BJPR, van Anrooij B, van Doormaal JJ, Dubois AEJ, Oude Elberink JNG. Fatal anaphylaxis to yellow jacket stings in mastocytosis: options for identification and treatment of atrisk patients. J Allergy Clin Immunol Pract 2017;5:1264-71PubMedCrossRef
22.
Michel J, Brockow K, Darsow U, Ring J,Schmidt-Weber CB, Grunwald T, et al. Added sensitivity of component resolved diagnosis in hymenoptera venom-allergic patients with elevated serum tryptase and/or mastocytosis. Allergy 2016;71:651-60PubMedCrossRef
23.
Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serumtryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. ClinExpAllergy 2003;33:1216-20
24.
Rueff F, Placzek M, Przybilla B. Mastocytosis and hymenopteravenomallergy. Curr Opin Allergy Clin Immunol 2006;6:284-8
25.
Gonzalez-de-Olano D, Alvarez-Twose I, Vega A, Orfao A, Escribano L. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy. 2011;3:637-51PubMedCrossRef
26.
Bonadonna P, Gonzalez-de-Olano D, Zanotti R, Riccio A, De FL, Lombardo C, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract 2013;1:474-8
27.
Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W, et al. Predictors of side effects during the buildup phase of venom immunotherapy for hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010;126:105-111.e5CrossRef
28.
Bonadonna P, Zanotti R, Pagani M, Bonifacio M, Scaffidi L, Olivieri E, et al. Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected. J Allergy Clin Immunol Pract 2018;6:1368-72PubMedCrossRef
29.
Alvarez-Twose I, Gonzalez de Olano D, Sánchez-Muñoz L, Matito A, Esteban-López MI, Vega A, et al. Clinical, biological and molecular characteristics of systemic mast cell disorders presenting with severe mediator-related symptoms. J Allergy Clin Immunol 2010;125:1269-78
30.
Stoevesandt J, Sturm GJ, Bonadonna P, Oude Elberink JNG, Trautmann A. Riskfactors and indicators of severe systemic insect sting reactions. Allergy 2019; https://​doi.​org/​10.​1111/​all.​13945PubMedCrossRef
31.
Arzt-Gradwohl L, Schrautzer C, Laipold K, Herzog SA, Stoevesandt J, Trautmann A, et al. No effect of antihypertensive drugs on severity of anaphylaxis and side-effects during venom immunotherapy. European academy of allergology and clinical immunology annual congress; 2019 June 1-5; Lisbon. Allergy 2019;74:233
32.
Matricardi PM, Bockelbrink A, Grüber C, Keil T, Hamelmann E, Wahn U, et al. Longitudinal trends of total and allergen-specific IgE throughout childhood. Allergy 2009;64:1093-8PubMedCrossRef
33.
Guan K, Li LS, Yin J. Use of sIgE/T-IgE in predicting systemic reactions: retrospective analysis of 54 honeybee venom allergy cases in North China. Chin Med J (Engl) 2016;129:2091-5PubMedPubMedCentralCrossRef
34.
Hamilton RG, MacGlashan DW Jr, Saini SS. IgE antibody specific activity in human allergic disease. Immunol Res 2010;47:273-84PubMedCrossRef
35.
Arzt L, Bokanovic D, Schrautzer C, Laipold K, Möbs C, PfütznerW, et al. Immunological differences between insect venom-allergic patients with and without immunotherapy and asymptomatically sensitized subjects. Allergy 2018;73:1223-31PubMedCrossRef
36.
Sturm GJ, Kranzelbinder B, Schuster C, Sturm EM, Bokanovic D, Vollmann J, et al. Sensitization to hymenoptera venoms is common, but systemic sting reactions are rare. J Allergy Clin Immunol 2014;133:1635-43CrossRef
37.
Golden DBK, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, et al. Stinging insect hypersensitivity. Ann Allergy Asthma Immunol 2017;118:28-54CrossRef
38.
Bilo MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy 2009;39:1467-76CrossRef
39.
Brown TC, Tankersley MS. The sting of the honeybee: an allergic perspective. Ann Allergy Asthma Immunol 2011;107:463-70. quiz471CrossRef
40.
Muller UR. Bee venom allergy in beekeepers and their family members. Curr Opin Allergy Clin Immunol 2005;5:343-7PubMedCrossRef
41.
Golden DB, Breisch NL, Hamilton RG, Guralnick MW, Greene A, Craig TJ, et al. Clinical and entomological factors influence the outcome of sting challenge studies. J Allergy Clin Immunol 2006;117:670-5CrossRef
42.
Fleming JT, Clark S, Camargo CA Jr., Rudders SA. Early treatment of food induced anaphylaxis with epinephrine is associated with a lower risk of hospitalization. J Allergy Clin Immunol Pract 2015;3:57-62PubMedCrossRef
43.
Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over- and underestimated parameters in severe hymenoptera venom induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol 2012;130:698-704CrossRef
44.
Arzt L, Bokanovic D, Schwarz I, Schrautzer C, Massone C, Horn M, et al. Hymenoptera stings in the head region induce impressive, but not severe sting reactions. Allergy 2016;71:1632-4PubMedCrossRef
45.
Solley GO. Stinging and biting insect allergy: an Australian experience. Ann Allergy Asthma Immunol 2004;93:53-537CrossRef
46.
Ruiz B, Serrano P, Verdú M, Moreno C. Sensitization to Api m 1, Api m 2, and Api m 4: association with safety of bee venom immunotherapy. Ann Allergy Asthma Immunol 2015;114:350-2CrossRef
47.
Bilò M, Pravettoni V, Bignardi D, Bonadonna P, Mauro M, Novembre E, et al. Hymenoptera venom allergy: management of children and adults in clinical practice. J Investig Allergol Clin Immunol 2019;29:180-205PubMedCrossRef
48.
Köhler J, Blank S, Müller S, Bantleon F, Frick M, Huss-Marp J, et al. Component resolution reveals additional major allergens in patients with honeybee venom allergy. J Allergy Clin Immunol 2014;133:1383-9CrossRef
49.
Blank S, Seismann H, Michel Y, McIntyre M, Cifuentes L, Braren I, et al. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy 2011;66:1322-9PubMedCrossRef
50.
Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998;101:606-12
51.
Hockenhull JE, lremeli M, Cherry MG, Mahon J, LaiM, Darroch J, et al. A systematic review of the clinical effectiveness and cost-effectiveness of pharmalgen for the treatment of bee and wasp venom allergy. Health Technol Assess 2012;16:1-110
52.
Catalá M, Gómez A, Ollo B, Gurpegui M, Talens M. Safety of hymenopteran venoms immunotherapy in a cluster schedule. A nursing perspective. An Sist Sanit Navar 2009;32:409-12
53.
Wöhrl S, Gamper S, Hemmer W, Heinze G, Stingl G, Kinaciyan T. Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol. 2007;144:137-42PubMedCrossRef
54.
Müller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001;107:81-6CrossRef
55.
Arseneau AM, Nesselroad TD, Dietrich JJ, Moore LM, Nguyen S, Hagan LL, et al. A 1-day imported fire ant rush immunotherapy schedule with and without premedication. Ann Allergy Asthma Immunol 2013;111:562-6CrossRef
56.
González-de-Olano D, Padial-Vilche MA, Núñez-Acevedo B, de-Calzada-Bustingorri MP, de-Andrés-Martín A, Caldas C, et al. Usefulness of omalizumab and sting challenge test in hymenoptera venom allergy and mastocytosis. J Investig Allergol Clin Immunol 2019;29:318-20PubMedCrossRef
57.
Droitcourt C, Ponvert C, Dupuy A, Scheinmann P, Abou-Taam R, de Blic J, et al. Efficacy of a short pretreatment with omalizumab in children with anaphylaxis to hymenoptera venom immunotherapy: a report of three cases. Allergol Int 2019;68:268-9PubMedCrossRef
58.
Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009;19:225-9
59.
Stretz E, Oppel EM, Räwer HC, Chatelain R, Mastnik S, Przybilla B, et al. Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose. Clin Exp Allergy 2017;47:1631-9CrossRef
60.
Clifford D, Ni Chaoimh C, Stanley E, O'B Hourihane J. A longitudinal study of hymenoptera stings in preschool children. Pediatr Allergy Immunol 2019;30:93-8PubMedCrossRef
61.
Cichocka-Jarosz E, Brzyski P, Tarczo´ n I, Jedynak-Wasowicz U, Tomasik T, Lis G. Quality of life in parents of children and adolescents after systemic sting reactions. Ann Agric Environ Med 2019;26:315-21PubMedCrossRef
Metadaten
Titel
Natural history of systemic reactions and risk factors in children and adults with Hymenoptera venom allergy
verfasst von
Darío Antolín-Amérigo
Berta Ruiz-León
A. Vega-Castro
Belén de la Hoz Caballer
Publikationsdatum
25.03.2020
Verlag
Springer Medizin
Erschienen in
Allergo Journal / Ausgabe 2/2020
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI
https://doi.org/10.1007/s15007-020-0745-0

Weitere Artikel der Ausgabe 2/2020

Allergo Journal 2/2020 Zur Ausgabe

Panorama

Das müssen Sie jetzt wissen!

AeDA/DGAKI informieren

eHealth - ein spannendes Forschungsfeld

Literatur kompakt

Allergenspezifische Immuntherapie mit einem Apfel pro Tag?

AeDA/DGAKI informieren

Fakten und Forderungen rund um das Kontaktekzem

AeDA/DGAKI informieren

Über die Bedeutung der Arzneimittelallergien in Klinik und Praxis

Literatur kompakt

Atopische Dermatitis: Anti-IL-31-Antikörper gegen Juckreiz und Entzündung

Passend zum Thema

ANZEIGE
Anaphylaxie

Es wäre so einfach, ein Leben zu retten – Wenn man nur daran denkt…

Anaphylaxie ist eine akute schwere allergische Reaktion und somit die schwerste Komplikation in der Allergologie. Darauf sollten Ärztinnen und Ärzte vorbereitet sein.

Bildnachweise